Curis (NASDAQ:CRIS) Stock Rating Upgraded by Wall Street Zen

Curis (NASDAQ:CRIS) was upgraded by Wall Street Zen from a “strong sell” rating to a “hold” rating in a research note issued to investors on Saturday.

A number of other analysts have also issued reports on the company. HC Wainwright restated a “buy” rating on shares of Curis in a report on Monday, August 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Curis in a report on Friday, July 17th. Finally, Zacks Research lowered Curis from a “hold” rating to a “strong sell” rating in a research report on Tuesday, August 11th. One investment analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Curis presently has an average rating of “Reduce” and an average price target of $43.00.

Curis Price Performance

CRIS stock opened at $1.58 on Friday. Curis has a 52-week low of $1.50 and a 52-week high of $39.00. The company’s 50 day simple moving average is $5.13 and its 200-day simple moving average is $11.11. The firm has a market capitalization of $3.30 million, a P/E ratio of -0.11 and a beta of 3.13.

Curis (NASDAQ:CRIS) last issued its quarterly earnings results on Friday, August 14th. The biotechnology company reported ($4.02) EPS for the quarter, beating the consensus estimate of ($6.95) by $2.93. Curis had a negative net margin of 80.29% and a negative return on equity of 2,365.94%. Sell-side analysts predict that Curis will post -24.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Nantahala Capital Management LLC acquired a new stake in shares of Curis during the 2nd quarter valued at $1,033,171,000. BlackRock Inc. acquired a new position in shares of Curis in the second quarter worth $28,000. XTX Topco Ltd purchased a new stake in shares of Curis during the fourth quarter worth $26,000. Squarepoint Ops LLC raised its holdings in shares of Curis by 46.2% during the fourth quarter. Squarepoint Ops LLC now owns 86,483 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 27,343 shares in the last quarter. Finally, Jane Street Group LLC raised its holdings in shares of Curis by 71.8% during the fourth quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 10,586 shares in the last quarter. Institutional investors and hedge funds own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.